admin, Author at Orphalan SA

Company News

Podcast: Naseem Amin, Orphalan CEO, discusses Wilson’s Disease and the potential advancements in its treatments on DNA Today

DNA Today is a multi-award-winning podcast and radio show exploring how genetics impacts our health. Host/Producer Kira Dineen interviews leaders in genetics including genetic counsellors, researchers, physicians, and patient advocates…

adminFebruary 6, 2023

Company News

Dr. Naseem Amin, Chief Executive Officer at Orphalan, discusses the announcement of the FDA approval of Cuvrior™

Dr. Naseem Amin, Chief Executive Officer at Orphalan, discusses the announcement of the FDA approval of Cuvrior™ in this video: https://www.youtube.com/watch?v=Yu2WsUwtayE

adminMay 3, 2022

Press Release

Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine

Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine. Paris, France 2 May 2022 – Orphalan…

adminMay 2, 2022

Press Release

FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease

Orphalan announces FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease —NDA supported by positive data from Phase 3…

adminSeptember 2, 2021

Company News Video

Top line results of CHELATE trial presented at International Liver Congress 2021. Top line Summary by Michael Schilsky, MD

adminJune 25, 2021

Company News

This morning, Dr Weiss presented our Phase 3 data at @EASL | The Home of Hepatology’s International Liver Congress 2021.

Friday 25 June Today we are excited to announce positive top-line data from our Phase 3 head-to-head trial of trientine tetrahydrochloride and d-penicillamine. This is the first trial of its…

adminJune 25, 2021

Press Release

Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson’s Disease

JUNE 25, 2021 - ORPHAN DISEASES — CHELATE trial confirmed trientine tetrahydrochloride was non-inferior to d-Penicillamine and met the primary endpoint of Non-Ceruloplasmin Copper (NCC) levels as a maintenance therapy…

adminJune 25, 2021

admin

Podcast: Naseem Amin, Orphalan CEO, discusses Wilson’s Disease and the potential advancements in its treatments on DNA Today

Dr. Naseem Amin, Chief Executive Officer at Orphalan, discusses the announcement of the FDA approval of Cuvrior™

Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine

FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease

Top line results of CHELATE trial presented at International Liver Congress 2021. Top line Summary by Michael Schilsky, MD

This morning, Dr Weiss presented our Phase 3 data at @EASL | The Home of Hepatology’s International Liver Congress 2021.

Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson’s Disease

Global Headquarters

Legal

Useful Links